Capmatinib Recruiting Phase 2 Trials for Renal Cancers / Papillary Renal Cell Carcinoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02019693A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer